Decision rule for stratification of patients with chronic heart failure of functional class II and III

The aim of the study was focused on the development of a decision rule for classifying patients as functional class (FC) II or III of chronic heart failure (CHF) by discriminant analysis with inflammatory markers.

Materials and methods. The study included CHF patients (n = 61) of both sexes. According to symptom severity, they were assigned to FC II (n = 20) and III (n = 41). In addition to conventional clinical and biochemical parameters to evaluate a patient’s state, parameters characterizing inflammation (IL-6, soluble IL-6 receptor, sgp130) were used. Statistically significant differences were revealed with the use of Mann – Whitney U test, Student’s t-test, Pearson’s χ2 test and Fisher’s exact test. Discriminant analysis was employed to formulate the decision rule. Receiver Operating Characteristic (ROC) analysis was used to evaluate the quality of the developed diagnostic test. The results were considered statistically significant at p < 0.05.

Results. Discriminant analysis included significantly different variables (age, brain natriuretic peptide, sgp130, CHF etiology, ischemic heart disease) and additional clinically important variables (diastolic and systolic arterial blood pressure (BP), IL-6). The decision rule for assigning patients to different CHF FC was developed. The optimum cut-off value was found with the use of the ROC curve with a sensitivity of 75.6% and specificity of 85%.

Conclusion. The decision rule for assigning CHF patients to FC II or III was developed using discriminant analysis. In addition to conventional clinical parameters, the model included the ones reflecting inflammatory processes (IL-6 and sgp130). ROC analysis revealed high quality of the model.

1. Рonikowski P., Voors A.A., Anker S.D., Bueno H., Cleland G.F. J., Coats J.S.A., Falk V., González-Juanatey J., Harjola V., Jankowska A.E., Jessup M., Linde C., Nihoyannopoulos P., Parissis T.J., Pieske B., Riley P.J., Rosano M.C.G., Ruilope M.L., Ruschitzka F., Rutten H. ., van der Meer P. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017; (1): 7–81. DOI: 10.15829/1560-4071-2017-1-7-81.

2. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007; 93 (9): 1137–1146. DOI: 10.1136/hrt.2003.025270.

3. Benjamin E.J., Virani S.S., Callaway C.W., Chamberlain A.M., Chang A.R., Cheng S., Chiuve S.E., Cushman M., Delling F.N., Deo R., de Ferranti S.D., Ferguson J.F., Fornage M., Gillespie C., Isasi C.R., Jiménez M.C., Jordan L.C., Judd S.E., Lackland D., Lichtman J.H., Lisabeth L., Liu S., Longenecker C.T., Lutsey P.L., Mackey J.S., Matchar D.B., Matsushita K., Mussolino M.E., Nasir K., O’Flaherty M., Palaniappan L.P., Pandey A., Pandey D.K., Reeves M.J., Ritchey M.D., Rodriguez C.J., Roth G.A., Rosamond W.D., Sampson U.K.A., Satou G.M., Shah S.H., Spartano N.L., Tirschwell D.L., Tsao C.W., Voeks J.H., Willey J.Z., Wilkins J.T., Wu J.H., Alger H.M., Wong S.S., Muntner P. Heart disease and stroke statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018; 137 (12): e67–492. DOI: 10.1161/CIR.0000000000000558.

4. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; 8: 7–13. DOI: 10.15829/1560-4071-2016-8-7-13.

5. Терещенко С.Н., Жиров И.В., Нарусов О.Ю., Мареев Ю.В., Затейщиков Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко А.Н., Насонова С.Н., Стукалова О.В., Саидова М.А., Скворцов А.А., Шария М.А., Явелов И.С. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический вестник. 2016; 2: 3–33.

6. Cainzos-Achirica M., Enjuanes C., Greenland P., McEvoy J.W., Cushman M., Dardari Z., Nasir K., Budoff M.J., Al-Mallah M.H., Yeboah J., Miedema M.D., Blumenthal R.S., Comin-Colet J., Blaha M.J. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Aherosclerosis (MESA). Atherosclerosis. 2018; 278: 217–225. DOI: 10.1016/j.atherosclerosis.2018.09.024.

7. Yan A.T., Yan R.T., Cushman M., Redheuil A., Tracy R.P., Arnett D.K., Rosen B.D., McClelland R.L., Bluemke D.A., Lima J.A. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomaticindividuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur. Heart J. 2010; 31 (7): 875–882. DOI: 10.1093/eurheartj/ehp454.

8. Shirazi L.F., Bissett J., Romeo F., Mehta J.L. Role of Inflammation in heart failure. Curr. Atheroscler. Rep. 2017; 19 (6): 27. DOI: 10.1007/s11883-017-0660-3.

9. Осипова О.А., Суязова С.Б., Власенко М.А., Годлевская О.М. Роль провоспалительных цитокинов в развитии хронической сердечной недостаточности. Российский медико-биологический вестник имени академика И.П. Павлова. 2013; 21 (2): 130–135. DOI: 10.17816/PAVLOVJ20132130-135.

10. Чепурнова Д.А., Самойлова Е.В., Анисимов А.А., Верин А.Д., Коротаева А.А. Компоненты рецепторного комплекса интерлейкина 6 при остром повреждении легких. Бюллетень экспериментальной биологии и медицины. 2017; 164 (11): 561–563. DOI: 10.1007/s10517-018-4042-9.

11. Korotaeva A.A., Samoilova E.V., Chepurnova D.A., Zhitareva I.V., Shuvalova Y.A., Prokazova N.V. Soluble glycoprotein 130 is inversely related to severity of coronary atherosclerosis. Biomarkers. 2018; 23 (6): 527–532. DOI: 10.1080/1354750X.2018.1458151.

12. Askevold E.T., Nymo S., Ueland T., Gravning J., Wergeland R., Kjekshus J., Yndestad A., Cleland J.G., McMurray J.J., Aukrust P., Gullestad L. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the сontrolled rosuvastatin multinational trial in heart failure (CORONA). Circ. Heart Fail. 2013; 6 (1): 91–98. DOI: 10.1161/CIRCHEARTFAILURE.112.972653.

13. Григорьев С.Г., Лобзин Ю.В., Скрипченко Н.В. Роль и место логистической регрессии и ROC-анализа в решении медицинских диагностических задач. Журнал инфектологии. 2016; 8 (4): 36–45. DOI: 10.22625/2072-6732-2016-8-4-36-45.